



October 14, 2008 12:00 PM Eastern Daylight Time 

Carl Zeiss Meditec and Optovue Settle Dispute

DUBLIN, Calif. & FREMONT, Calif.--([BUSINESS WIRE](#))--Carl Zeiss Meditec Inc. (CZMI) and Optovue Corp. announced that the parties have resolved their legal disputes pending in the Northern District of California and in Massachusetts Superior Court. The parties have agreed to licensing and other terms and assurance of protection of disputed intellectual property. Remaining terms of the settlement agreement are confidential.

About Optovue (www.optovue.com)

Optovue Corp., founded in 2006 by pioneers in the field of optical coherence tomography (OCT), is a privately held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. The company is headquartered in Fremont, CA, with European operations in Heidelberg, Germany.

Optovue has developed and markets the RTVue™ Fourier Domain OCT, the first and only FDA-cleared spectral domain OCT capable of imaging both the front (cornea) and back (retina) of the eye in a single system. There are more than 900 RTVue systems installed worldwide. Optovue has achieved widespread market acceptance through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback.

About Carl Zeiss Meditec AG (www.meditec.zeiss.com)

Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation.

The company has two primary areas of activity: In the field of ophthalmology Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. The company's system solutions are employed in all phases of the disease management, from diagnosis to treatment and follow-up. Carl Zeiss Meditec has always applied its technological expertise to product innovations. These innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyser, the Cirrus HD-OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. The product portfolio in ophthalmic surgery is rounded off by intraocular lenses and consumables.

In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualisation solutions for a very broad range of applications, such as tumor and vascular surgery in the head region and/or spinal surgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by visualisation systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany, the USA (Carl Zeiss Meditec, Inc., Dublin), in Japan, Spain and France.

Contacts

Carl Zeiss Meditec, Inc.
Jackie Ferreira, Director of Marketing Communications
925-557-4488
j.ferreira@meditec.zeiss.com

or
Asclepius Communications for Optovue
Susan Scher
415-339-9404
sscher@medpr.com

Permalink: <http://www.businesswire.com/news/home/20081014006219/en>

